Crinetics (CRNX) announced that the first patient has been dosed in the CALM-CAH Phase 3 trial evaluating investigational candidate atumelnant, a novel, once-daily, oral adrenocorticotropic hormone receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- CRNX, CYTK, MDGL, SLNO: Top Analyst Outlines Her ‘Top Biotech Ideas for 2026’
- Crinetics announces first patient dosed in Phase 1/2 study of CRN09682
- Crinetics randomizes first patient in CAREFNDR trial
- Buy Rating Justified by Strategic Initiatives and Growth Prospects at Crinetics Pharmaceuticals
- Crinetics price target raised to $45 from $40 at Goldman Sachs